XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has made a significant announcement, along with its exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). The companies have completed all actions and procedures required for the European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System. The announcement noted that ISO 13485 approval for 3a as a medical device manufacturer is expected in the next few weeks; 3a also anticipates European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for COVID-ID Lab by early March. The exclusive lab is designed to be a rapid, accurate and robust test system that offers increased convenience and portability with lower operating costs. XPhyto noted that it is in discussions with potential distribution and wholesale partners in Europe and the Middle East, with a European sales launch target of April 2021. A bioscience accelerator at the leading-edge of the life science industry, XPhyto and 3a are also working together to develop oral biosensor screening tests for detection of a range of bacterial and viral infectious diseases, including influenza A, group A strep, stomatitis, periimplantitis and periodontitis. The announcement also noted that XPhyto has additional pandemic-focused biosensors in development, specifically targeting swine flu and avian flu. XPhyto anticipates commercial launch of its first biosensor product later this year. “We are very pleased with the team’s swift development progress,” said XPhyto CEO and director Hugh Rogers. “Our goal was to create the fastest and most portable COVID-19 PCR test on the market. We are confident in our prospects for an expedited approval and look forward to commercial launch in short order.”
For more information, visit https://ibn.fm/xbFLA
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php